Media Library

Access photos, images, or videos for stories in development. If you are a member of the working press and need a resource that is not available on this website, please e-mail your request to and we will make every effort to respond as soon as possible. Please read our terms for usage.

Key Facts

updated March 2021

Chief Executive Officer:
New York City
Web Address:
NYSE Listing:
Total Revenues:
$42.5 billion in 2020
R&D Investment:
$11.1 billion in 2020, which included the discovery and development of new medicines for patients
2020 Prioritized Brands Product Revenue:

REVLIMID® (lenalidomide), $12.1 billion

ELIQUIS® (apixaban), $9.1 billion

OPDIVO®(nivolumab), $7 billion

ORENCIA® (abatacept), $3.2 billion

POMALYST® (pomalidomide), $3.1 billion

SPRYCEL® (dasatinib), $2.1 billion

YERVOY® (ipilimumab), $1.7 billion

ABRAXANE® (paclitaxel protein-bound particles for injectable suspension) (albumin-bound), $1.2 billion

EMPLICITI® (elotuzumab), $381 million

REBLOZYL® (luspatercept-aamt), $274 million

INREBIC® (fedratinib), $55 million

ONUREG® (azacitidine tablets), $17 million

ZEPOSIA® (ozanimod), $12 million

Please click on the product links to see the Full Prescribing Information for ABRAXANE®, ELIQUIS®, EMPLICITI®, INREBIC®, ONUREG®OPDIVO®, ORENCIA®, POMALYST®, REBLOZYL®REVLIMID®SPRYCEL®, YERVOY® and ZEPOSIA® including Boxed WARNINGS for ABRAXANE®, ELIQUIS®INREBIC®, POMALYST®, REVLIMID®, and Boxed WARNINGS for YERVOY® regarding immune-mediated adverse reaction.

Bristol Myers Squibb Corporate B-roll

Overview B-roll

This B-roll includes a collection of footage of Bristol Myers Squibb campus exteriors, corporate signage, research and development, and manufacturing facilities.

Usage Rights & Restrictions: These media assets are free for editorial broadcast, print, online and radio use. They are restricted for other purposes.

Bristol Myers Squibb
Building Signage
Scientific Media Resources
Disease State Infographics
Disease State Infographics